China’s top health authority has granted Adcentrx Therapeutics approval to proceed with trials for ADRX-0405, an investigational STEAP1 antibody-drug conjugate aiming to treat late-stage solid tumors, including prostate cancer. Building on progress from its U.S. Phase 1a/1b study, the company aims to broaden the trial’s reach and accelerate patient enrollment by including clinical centers in China.

Mdxhealth has unveiled new findings from Oxford’s ProMPT Study, which show that the Genomic Prostate Score (GPS) test can predict adverse outcomes for prostate cancer patients. Presented at EAU 2026, this research highlights the test’s broad relevance across multiple treatment approaches.